Cardiofaciocutaneous syndrome and immunodeficiency: data from an international multicenter cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Di Majo Benedetta Elena, Leoni Chiara, Cartisano Eleonora, Fossati Chiara, Viscogliosi Germana, Trevisan Valentina, Bruno Lucia Pia, Conti Francesca, Moratti Mattia, Monaco Emilia, Rigante Donato, Rivalta Beatrice, Cancrini Caterina, Szczawińska-Popłonyk Aleksandra, Jamsheer Aleksander, Obara-Moszyńska Monika, Zakharova Viktoria, Shcherbina Anna, Rodina Julija, Tüysüz Beyhan, Jamuar Saumya Shekhar, Lim Jiin Ying, Goh Jeannette, Cereda Anna, Agovino Teresa, Contaldo Ilaria, Gambardella Maria Luigia, Balduzzi Adriana Cristina, Cherubino Alessia, Marrocco Giovanni Antonio, Bellesi Silvia, Carusi Valentina, Rumi Gabriele, Biondi Andrea, Zampino Giuseppe, Saettini Francesco
Аннотация
METHODS: We conducted a retrospective, multicenter observational study to investigate the immunological phenotype of CFCS. Clinical features, immune-related manifestations, and laboratory parameters were analyzed to delineate the immunological profile of affected individuals.
RESULTS: A total of 56 patients with a confirmed clinical and molecular diagnosis of CFCS were included, with a median age at evaluation of 13 years (range: 1-39 years). Increased susceptibility to infections was reported in 18/56 patients (32%), while autoimmune manifestations were observed in 14/56 patients (25%). Common immunological findings included monocytosis (32%), lymphopenia (21%), and hypogammaglobulinemia, with decreased IgG, IgA, or IgM levels in 21%, 40%, and 35% of patients, respectively. Genotype-phenotype analysis revealed that BRAF mutations were predominantly associated with T-cell lymphopenia, whereas MAP2K1 mutations were linked to monocytosis, reduced naïve and switched-memory B cells, and hypogammaglobulinemia. Immunodeficiency-related treatments, including immunoglobulin replacement therapy, antibiotic prophylaxis, or immunosuppressive therapy, were administered to 6/56 patients (11%).
CONCLUSIONS: CFCS is associated with recurrent yet heterogeneous immunological abnormalities, including lymphopenia, hypogammaglobulinemia, and increased infection susceptibility. Given these findings, routine immunological assessment should be considered in CFCS patients to facilitate early detection and appropriate management of immune dysfunction.